PMID- 33792026
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20210927
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 193
IP  - 3
DP  - 2021 May
TI  - The detection of circulating plasma cells may improve the Revised International 
      Staging System (R-ISS) risk stratification of patients with newly diagnosed 
      multiple myeloma.
PG  - 542-550
LID - 10.1111/bjh.17118 [doi]
AB  - The Revised International Staging System (R-ISS) stratifies patients affected by 
      Multiple Myeloma (MM) into three distinct risk groups: R-ISS I [ISS Stage I, 
      Standard-Risk cytogenetics and normal Lactase DeHydrogenase (LDH)], R-ISS III 
      (ISS stage III and either high-risk cytogenetics or high LDH) and R-ISS II (any 
      other characteristics). With the aim to verify whether the three R-ISS groups 
      could be divided into subgroups with different prognostic factors based on the 
      detection of Circulating Plasma Cells (CPCs) at diagnosis, in this retrospective 
      analysis, we evaluated 161 patients with MM treated at our centre between 2005 
      and 2017. In all, 57 patients (33.9%) were staged as R-ISS III, 98 (58.3%) as 
      R-ISS II and six (3.6%) as R-ISS I. CPCs were detected in 125 patients (74.4%), 
      while in 43 patients (25.6%) no CPCs were seen. Our analysis revealed that 
      Overall Survival (OS) and progression-free survival (PFS) rates in R-ISS II 
      patients were higher in the subgroup without CPCs compared to the subgroup with 
      >/=1 CPCs (OS: 44.7% vs. 16.3%, P = 0.0089; PFS: 27.8% vs. 8.1%, P = 0.0118). Our 
      present findings suggest that the detection of CPCs at diagnosis may be used as a 
      further prognostic biomarker to improve the risk stratification of patients with 
      MM staged as R-ISS II.
CI  - (c) 2021 British Society for Haematology and John Wiley & Sons Ltd.
FAU - Galieni, Piero
AU  - Galieni P
AUID- ORCID: 0000-0002-0793-264X
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Travaglini, Fosco
AU  - Travaglini F
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Vagnoni, Davide
AU  - Vagnoni D
AD  - UOC Clinical Pathology, ASUR Marche, Civitanova Marche Hospital, Costamartina, 
      Italy.
FAU - Ruggieri, Miriana
AU  - Ruggieri M
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Caraffa, Patrizia
AU  - Caraffa P
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Bigazzi, Catia
AU  - Bigazzi C
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Falcioni, Sadia
AU  - Falcioni S
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Picardi, Paola
AU  - Picardi P
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Mazzotta, Serena
AU  - Mazzotta S
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Troiani, Emanuela
AU  - Troiani E
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Dalsass, Alessia
AU  - Dalsass A
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Mestichelli, Francesca
AU  - Mestichelli F
AUID- ORCID: 0000-0002-5391-1671
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Angelini, Mario
AU  - Angelini M
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Camaioni, Elisa
AU  - Camaioni E
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Maravalle, Denise
AU  - Maravalle D
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Angelini, Stefano
AU  - Angelini S
AUID- ORCID: 0000-0001-6720-3564
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
FAU - Pezzoni, Valerio
AU  - Pezzoni V
AUID- ORCID: 0000-0002-4313-5779
AD  - Department of Haematology and Stem Cell Transplantation Unit, C. e G. Mazzoni 
      Hospital, Ascoli Piceno, Italy.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20210401
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Immunologic Factors)
RN  - 0 (Proteasome Inhibitors)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Autografts
MH  - Dexamethasone/administration & dosage
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Immunologic Factors/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - *Multiple Myeloma/blood/diagnosis/mortality/therapy
MH  - Neoplasm Staging
MH  - Neoplastic Cells, Circulating/*metabolism
MH  - Plasma Cells/*metabolism
MH  - Proteasome Inhibitors/administration & dosage
MH  - Retrospective Studies
MH  - *Stem Cell Transplantation
MH  - Survival Rate
OTO - NOTNLM
OT  - circulating plasma cells
OT  - multiple myeloma
OT  - prognostic biomarker
OT  - risk stratification
OT  - survival time
EDAT- 2021/04/02 06:00
MHDA- 2021/09/28 06:00
CRDT- 2021/04/01 06:44
PHST- 2020/06/26 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2021/04/02 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
PHST- 2021/04/01 06:44 [entrez]
AID - 10.1111/bjh.17118 [doi]
PST - ppublish
SO  - Br J Haematol. 2021 May;193(3):542-550. doi: 10.1111/bjh.17118. Epub 2021 Apr 1.